Clinical trial

CAR T Cells in Mesothelin Expressing Cancers

NCT03054298

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-04-06

PhasePHASE1

Study timeline

Study start (actual)2017-04-06Date precision: day

Registry last updated2025-04-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Adenocarcinomaverified · MONDO: lung adenocarcinoma

Ovarian Cancerverified · MONDO: ovarian cancer

Peritoneal Carcinomaverified · MONDO: peritoneal carcinoma

Fallopian Tube Cancerverified · MONDO: fallopian tube cancer

Mesotheliomas Pleuralunresolved

Mesothelioma Peritoneumunresolved

Interventions

huCART-meso cellsBIOLOGICAL

Sponsors & collaborators

University of Pennsylvanialead sponsor

National Institutes of Health (NIH)collaborator

Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)collaborator

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03054298 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.